# Ashland Inc. – Consensus ‘buy’ rating and 17.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/ashland-inc.consensus-buy-rating-and-17.2-upside-potential/4121169410
- Published: 2024-08-23T12:37:24+01:00
- Author: Charlotte Edwards

**Ashland Inc.** with ticker code (ASH) now have 9 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The range between the high target
price and low target price is between $110.00 and $92.00 calculating the average
target price we see $102.11. Given that the stocks previous close was at $87.14 
this would imply there is now a potential upside of 17.2%. There is a 50 day moving
average of $92.50 and the 200 day MA is $90.61. The company has a market capitalization
of 4.23B. Currently the stock stands at: $86.68 USD

 The potential market cap would be $4,959,903,673 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 25.35, revenue per share of $41.54
and a 1.21% return on assets.

Ashland Inc. is a global additives and specialty ingredients company. It serves 
customers in a range of consumer and industrial markets, including architectural
coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal
care and pharmaceuticals. Its segments include life sciences, personal care, specialty
additives, and intermediates. The life sciences segment includes pharmaceuticals,
nutraceuticals and nutrition, and diagnostic films and agricultural chemicals. The
personal care segment skin and sun care, hair care, oral care, home care, and others.
The specialty additives segment includes coatings, construction, and energy. The
intermediates segment produces and supplies butanediol (BDO), Tetrahydrofuran (THF),
n-methyl-pyrrolidone (NMP) and gamma-butyrolactone (GBL, BLO) in addition to other
downstream products. Its products include acrylates, aquaflow, biofunctionals, cellulosics,
cyclodextrins, encapsulates, emollient esters, emulsifiers, and others.

Share on: